LA CANCEROLOGIE FACE A LA PANDEMIE DU COVID-19

Cancer incidence in Morocco: report from Casablanca registry 2005-2007.

Cancer incidence in Rabat, Morocco: 2006-2008

Epidemiological and pathological features of cancer in Fez Boulemane region, Morocco

The Practice of Medical Oncology in Morocco: The National Study of the Moroccan Group of Trialist in Medical Oncology (EVA-Onco).

Determinants of “lost to follow-up” status among patients treated for cancer in Morocco: situation before the Cancer Plan.

Lost to follow-up in radiotherapy: experience of the National Institute of Oncology in Morocco.

The European Organization for Research and Treatment of Cancer quality of life questionnaire-BR23 BreastCancer-Specific Quality of Life Questionnaire: psychometric properties in a Moroccan sample of breast cancer patients.

Efficacy and safety of bevacizumab in the treatment of human epidermal growth factor receptor type 2 negative metastatic breast cancer: About a large series in moroccan population.

Demographic, clinical, pathological, molecular, treatment characteristics and outcomes of nonmetastatic inflammatory breast cancer in Morocco: 2007 and 2008.

Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patients.

The CHEK2 1100delC allelic variant is not present in familial and sporadic reast cancer cases from Moroccan population.

Association of TP53 PIN3 polymorphism with breast cancer in Moroccan population.

Frequency and Spectrum of KRAS Mutations in Moroccan Patients with Lung Adenocarcinoma.

Frequency and type of epidermal growth factor receptor mutations in moroccan patients with lung adenocarcinoma.

Targeted therapy in thyroid cancer: Towards a treatment card.

Images in clinical medicine. Bilateral lower palpebral MALT lymphoma.

Vismodegib: the proof of concept in Basal cell carcinoma.

Clinical prognostic factors in locally advanced nasopharyngeal carcinoma in Moroccan population.